Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Novel estrogen-platinum(II) hybrid molecules evaluated vs. gynecologic cancers
January 20th, 2005
Biochemists at the University of Quebec have been testing novel estrogen-platinum(II) hybrid molecules against uterine and ovarian cancer cell lines. V. Gagnon and colleagues recently reported, "the synthesis of a series of original 17beta-estradiol-linked platinum(II) hybrid molecules. The biological activity of these compounds was evaluated in vitro on estrogen dependent and independent (ER+ and ER-) human uterine and ovarian cancers." According to the researchers, "The hybrid molecules present higher affinity than that of 17beta-estradiol for the estrogen receptor alpha (ERalpha)." They said their "study further confirms that...
Source: Women's Health Weekly (2005-01-20)
|
